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Inflammatory mediators are associated with 1-year
mortality in critical limb ischemia
Jamal Barani, MD,a Jan-Åke Nilsson, BA,b Ingrid Mattiasson, MD, PhD,a Bengt Lindblad, MD, PhD,a
and Anders Gottsäter, MD, PhD,a Malmö, Sweden
Objective: The atherosclerotic process has inflammatory features. Patients with peripheral atherosclerosis and critical limb
ischemia have a poor prognosis. This study evaluated the hypothesis that inflammatory markers are associated with
mortality among patients admitted to the hospital because of critical limb ischemia.
Methods: This was a prospective, single-center, 1-year, follow-up study of 259 consecutive patients with critical limb
ischemia who were admitted to a secondary referral center of vascular diseases. Interventions included evaluation of
intercurrent disease, ankle and arm blood pressures, plasma glucose and lipid levels, plasma homocysteine, cardiolipin
antibodies, resistance to activated protein C, plasma endothelin-1, and the inflammatory mediators tumor necrosis
factor-, interleukin-6, neopterin, high-sensitivity C-reactive protein, CD40 ligand, and 8-iso-prostaglandin F in
plasma. The main outcome measure was total mortality and causes of death assessed 1 year after admission.
Results: During the first year after admission, 61 patients (24%) died. These patients were older (P < .0001), showed a
higher leukocyte count (P  .0011) and levels of serum creatinine (P < .0001), lower levels of high-density lipoprotein
(HDL) cholesterol (P  .003) and frequency of active treatment (P  .014) than the 198 (76%) survivors. More
nonsurvivors had gangrene (P < .0001), and fewer (P  .004) had lipid-lowering treatment. The plasma levels of
interleukin-6 (P < .0001), tumor necrosis factor- (P < .0001), neopterin (P < .0001), and high-sensitivity C-reactive
protein (P  .002) at admission for critical limb ischemia were all significantly lower in the survivors, whereas there was
no difference concerning CD40 ligand. In logistic regression adjusted for age, sex, lipid-lowering therapy, active
treatment, gangrene, leukocyte count, creatinine, and serum HDL cholesterol, the inflammatory mediators tumor
necrosis factor- (P  .0084), neopterin (P  .0035), but not interleukin-6 (P  .585) or high-sensitivity C-reactive
protein (P .314) were independent risk variables of death within 1 year.
Conclusions: Increased age, leukocyte count, creatinine, and inflammatory mediators, together with gangrene, were
associated with 1-year mortality despite intervention in critical limb ischemia. For tumor necrosis factor- and neopterin
in plasma, this association was independent of the other parameters. ( J Vasc Surg 2005;42:75-80.)Epidemiology and pathophysiology are less well stud-
ied in critical limb ischemia than in atherosclerotic manifes-
tations in the coronary and precerebral arteries. In particu-
lar, the importance of leukocytes and inflammatory
reactions for the pathophysiology of ischemic vascular dis-
ease1,2 has been studied predominantly in subjects with
coronary artery disease. Although inflammatory markers
have been evaluated among asymtomatic3-5 and sym-
tomatic3,5,6 subjects with peripheral arterial disease, their
prognostic importance in critical limb ischemia is not estab-
lished.
The importance of inflammatory reactions may be more
difficult to clarify in critical limb ischemia because patients
with this condition, by definition,7 often have ischemic leg
ulcers featuring inflammatory processes that might affect the
patterns of inflammatory mediators. Concerning risk factors
of atherosclerosis, patients with critical limb ischemia are also
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nary or precerebral atherosclerosis.8-10
Tumor necrosis factor- (TNF-),11 neopterin,12 and
interleukin-6 (IL-6) are inflammatory mediators reported
to be involved in atherogenesis.13 The expression of the
immune mediator CD40 ligand is also increased in cells
involved in atherogenesis.14,15 Endothelin-1 (ET-1), a va-
soconstrictive factor produced by the endothelium that
promotes the initiation and progression of atherosclerosis, 16 is
another substance involved in the pathogenesis of atheroscle-
rosis.17 Isoprostanes, including 8-epi-prostaglandin (PG)F2 ,
are prostaglandin F2-like compounds
18,19 measured as mark-
ers for lipid peroxidation that are believed to contribute to
atherosclerosis and thrombosis.20
The 1-year mortality in patients with critical limb isch-
emia is about 20%7,21,22 and is influenced by features of
inflammation such as leukocyte count and fibrinogen.23
The aim of the present observational, hypothesis-generating
study was to evaluate whether, at admission, plasma levels
of TNF-, neopterin, IL-6, CD40 ligand, ET-1, or 8-epi-
prostaglandin (PG)F2 were associated with total 1-year
mortality in consecutive patients admitted to hospital be-
cause of critical limb ischemia.
METHODS
Patients. The Department of Vascular Diseases at
Malmö University Hospital is the single referral center for
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ernmost health-care districts in Sweden (723,750 inhabit-
ants in 2001). During a 14-month period, 316 consecutive
patients were referred to the department with a confirmed
diagnosis of critical limb ischemia, and 259 (82%) con-
sented to be in the present study. With respect to age, sex,
or blood pressure, they did not differ from patients who
declined to participate. The study protocol conformed to
the Declaration of Helsinki, and all participants gave writ-
ten informed consent. The Lund University Regional Eth-
ical Review Board approved the study.
The diagnosis of critical limb ischemia was made in
accordance with TransAtlantic Inter-Society Consensus
scientific criteria7 of ulceration, gangrene, or rest pain
caused by peripheral arterial disease proven by ankle pres-
sure (50 to 70mmHg), reduced toe pressure (30 to 50
mm Hg), or reduced transcutaneous oxygen tension
(TCPO2). Diagnosis was confirmed by an experienced vas-
cular surgery consultant and toe pressure measurements in
those patients where the arteries in the affected leg were
noncompressible and the ankle pressure was50 to 70mm
Hg.7 One-year mortality after admission and causes of
death were assessed from the Swedish Board of Health and
Welfare.
Patient variables. Body mass index was calculated as
weight in kilograms/height in m2. We measured arm and
ankle blood pressures with a sphygmomanometer with the
patient in the supine position. Gangrene was defined as
visible tissue loss on clinical examination.
Venous blood glucose levels were determined by a
routine hexokinase method. Serum levels of triglycerides
and total, low-density lipoprotein (LDL), and high-density
lipoprotein (HDL) cholesterol were determined by a DAX
48 automatic analyzer (Bayer AB, Gothenburg, Sweden).24
Plasma homocysteine was analyzed by a high-perfor-
mance liquid chromatographic assay.25-27 The reference
values were 18 mol/L and the interassay coefficient of
variation was 3.7%. We tested resistance to activated pro-
tein C (APC) with a predilution of sample plasma in factor
V-deficient plasma, CV was 7%. The method28 has a spec-
ificity and sensitivity of near 100% for the factor V:Q506
allele, which is the mutation responsible for APC resistance
with so-called low APC ratio.
Anticardiolipin antibodies were evaluated in serum by
enzyme-linked immunosorbent assay (ELISA).29 The ref-
erence values were20 IgG phospholipid units, and values
40 IgG phospholipid units were considered positive.
Analysis of inflammatory mediators. Plasma TNF-
and IL-6 were measured by ELISA using commercially
available test kits (Pharmingen, San Diego, Calif). The
detection limits were 0.12 pg/mL and 0.70 pg/mL, re-
spectively.
Plasma neopterin was determined by ELISA (Henning,
Berlin, Germany). The detection limit was 2 nmol/L, and
the intra- and interassay coefficients of variation were 1.7%
and 8.2%.
Serum high-sensitivity C-reactive protein (hs-CRP)
was measured by rate turbidimetry at the Department ofClinical Chemistry,MalmöUniversityHospital. The detec-
tion limit was 0.2 mg/L, and the interassay coefficients of
variation were 6% at 15 mg/L and 5 % at 85 mg/L.
We measured plasma ET-1 by radioimmunoassay (Ni-
chols Institute Diagnostics, San Juan Capistrano, Calif).
The detection limit was 1.0 pg/mL, the intra-assay coeffi-
cient of variation based on pooled samples was 11.3%, and
the interassay variation was 22%.
Plasma 8-epi-PGF2 was measured by an enzyme im-
munoassay using commercially available test kits (Cayman
Chemical Company, Ann Arbor, Mich). The detection
limit was 3.9 pg/mL.
Serum CD40 ligand was analyzed by an immunoassay
using commercially available test kits (R & D Systems Inc,
Minneapolis, Minn). The detection limit was 2.1 pg/mL.
Statistics. We evaluated the differences between sur-
vivors and nonsurvivors with theMann-Whitney U test and
the 2 test. The independent predictive effect of inflamma-
tory mediators for 1-year mortality was tested in step-wise
logistic regression adjusted for all variables that were found
to differ between survivors and nonsurvivors. All tests were
two-tailed, and P  .05 was considered significant. The
results are presented as mean  SD. All variables were
recorded in a database, and statistical analyses and calcula-
tions were performed with the statistical software StatView
5.0 (SAS Institute, Cary, NC).
RESULTS
During the first year after admission because of critical
limb ischemia, 80 (25%) of the 316 patients died. Among
the 57 patients who declined study participation, 19 (33%)
died; 61 (24%) of the included 259 patients died (P 
.0310). The cause of death was cardiac or vascular disease in
45 (74%). Included patients who died within 1 year after
admission were older (P  .0001). They showed a higher
leukocyte count (P  .0011) and serum creatinine levels
(P  .0001), and lower levels of HDL-cholesterol (P 
.003) than did the 198 (76%) surviving patients (Table I).
Of the five patients undergoing dialysis, four died during
the 1-year follow-up.
The nonsurvivors had a higher prevalence of gangrene
(P  .0001) and a lower prevalence of lipid-lowering
treatment (statins in 59 of 61 patients with lipid-lowering
treatment) (P  .004).
On the other hand, no differences were noted between
the survivors and the nonsurvivors regarding sex, blood
pressures, prevalence of diabetes mellitus (Table I), or the
frequency of endovascular, surgical, or medical treatment
of critical ischemia during the 1-year follow-up (Table II).
The total frequency of any active surgical, endovascular, or
medical treatment was higher (P  .014) in survivors,
however (Table I).
Plasma levels of the inflammatory mediators IL-6 (P
.0001), TNF- (P  .0001), neopterin (P  .0001), and
hs-CRP (P  .0024) at hospital admission because of
critical limb ischemia were all significantly lower in the
survivors than in the nonsurvivors (Fig). However, plasma
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between the groups (Table I).
In logistic regression adjusted for age, sex, lipid-lowering
therapy, gangrene, leukocyte count, and serum levels of
creatinine and HDL cholesterol, plasma levels of the in-
flammatory mediators TNF- (P .0084), neopterin (P
.0035), but not serum hs-CRP (P .314), or p-IL-6 (P
.586) were independently associated with death within 1
year. Because of their high internal correlation, however,
this association disappeared for TNF- (P  .486) and
neopterin (P .272) when all inflammatory variables were
adjusted for each other (Table III).
To exclude the possibility that differences in inflamma-
tory mediators between the survivors and the nonsurvivors
were explained by gangrene, the two groups were com-
pared after patients with gangrene were excluded. This
analysis revealed that the differences between the survivors
Table I. Results in patients who survived or died 1 year af
Survivors* (n 
Demographic data
Age (years) 74  10
Male sex 99 (50)
BMI (kg/m2) 25.1  4.7
Hemoglobin (g/l) 123  18
Leukocyte count 9.2  3.1
Platelet count 302  11
Glucose (mmol/L) 5.5  4.4
Serum creatinine (mol/L) 118  81
Ulceration 120 (61)
Gangrene 16 (8)
Aortoiliacal AS 18 (9)
Multisegmental AS 30 (15)
Infrainguinal AS 149 (75)
Ankle-brachial index 0.31  0.2
Ankle BP affected leg (mm Hg) 45  31
Risk factors and treatment
Current smoker 69 (35)
Diabetes mellitus 100 (51)
Arterial hypertension 141 (71)
Systolic BP (mm Hg) 149  25
Diastolic BP (mm Hg) 76  15
Cholesterol (mmol/L) 4.83  1.2
LDL (mmol/L) 2.90  1.0
HDL (mmol/L) 1.18  0.4
Triglycerides (mmol/L) 1.69  0.9
Lipid-lowering drugs 55 (28)
Active treatment 168 (85)
Homocysteine (mol/L) 16.7  6.8
Cardiolipin antibodies 60 (30)
Factor V Leyden 27 (14)
Inflammatory markers
Endothelin-1 (pg/mL) 1.63  1.1
8-epi-PGF2 (pg/mL) 243  21
High-sensitivity CRP (mg/L) 33.6  56
IL-6 (pg/mL) 21.5  37
TNF- (pg/mL) 1.73  1.2
Neopterin (nmol/L) 19.1  20
CD 40 ligand (pg/mL) 644  10
BMI, Body mass index; BP, blood pressure; AS, atherosclerosis; LDL, low-d
*Data are mean  SD or n (%).
†Value is significant.and the nonsurvivors persisted for IL-6 (P  .0006),TNF- (P  .0004), neopterin (P  .0002), and hs-CRP
(P .227). Antibiotic treatment was given on admission to
12 (36%) of the patients with gangrene and to 56 (25%) of
the patients without gangrene (P  .1577).
DISCUSSION
Our study confirmed the ominous prognosis for pa-
tients with critical limb ischemia, with a one-year mortality
of 26% mainly due to cardiovascular disease, comparable to
figures previously published.21,22 The mortality was
slightly higher among the patients not consenting to study
inclusion, probably because some critically ill patients with
high mortality were not able to sign written consent. Fur-
thermore and most importantly, our study showed that the
inflammatory mediators IL-6, TNF-, neopterin, and hs-
CRP were associated with 1-year mortality in subjects with
critical limb ischemia. For TNF- and neopterin, this asso-
dmission for critical limb ischemia
) Nonsurvivors* (n  61) P
80  10 .0001†
39 (64) .081
24.8  4.0 .903
120  19 .206
10.8  4.2 .011†
329  134 .067
5.9  4.3 .516
183  175 .0001†
35 (57) .653
17 (28) .0001†
1 (2) .051
13 (21) .258
48 (79) .582
0.32  0.26 .994
44  31 .851
15 (25) .134
35 (57) .434
40 (66) .313
142  28 .576
73  12 .236
4.57  1.11 .140
2.82  0.93 .629
1.01  0.44 .003†
1.64  1.10 .838
6 (10) .004†
38 (62) .014†
18.3  7.2 .078
11 (18) .131
6 (10) .283
1.65  0.72 .583
295  269 .059
49.4  62.1 .002†
40.5  60.0 .0001†
3.71  6.57 .0001†
49.7  66.2 .0001†
1136  3126 .643
lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive protein.ter a
198
2
1
4
6
3
3
1
9
.5
.5
4
.6
34
ensityciation was independent of other variables such as age, sex,
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function, and HDL-cholesterol levels.
A limitation of our study, however, is that we cannot
draw any conclusions about possible relationships between
the levels of inflammatory mediators and the efficacy of
interventions in our patients. Further studies are needed,
and as we have made only a predictive sampling showing
the associations between inflammatory mediators and mor-
tality, our results cannot be used to determine the best
treatment of a certain patient. Elevated levels of inflamma-
tory mediators are only indicators of a more severe progno-
Increased levels of the inflammatory mediators interleu
0.0001), and neopterin in plasma (P 0.0001) and high
among patients with critical limb ischemia who did not su
patients
Table II. One-year outcome related to different types of t
1-year follow-up
Type of treatment N (%)
1-yea
(% s
Femoropopliteal or distal bypass 46 (18) 1
Endarterectomy, X-over, Y-graft 22 (8)
PTA 34 (13)
Endovascular stenting 33 (13)
SAP 54 (21) 1
Nonsuccessful SAP 11 (4)
Iloprost infusion 6 (2)
Conservative 53 (20) 1
Total 259 6
PTA, Percutaneous transluminal angioplasty; SAP, subintimal angioplasty.sis.Other limitations of the study are that it was a descrip-
tive, observational, hypothesis-generating study performed
at a single center. It lacked a case-control design and a
healthy comparison group.
Among patients with critical limb ischemia, inflamma-
tory mediators can be hypothesized to originate partly from
ulcers and gangrene of the ischemic limb, but also from the
general atherosclerotic process. Furthermore, the IL-6
gene is upregulated in the hypoperfused musculature of
subjects with critical limb ischemia,30 and IL-6 has been
reported to be increased in symptomatic peripheral artery
(P  .0001), tumor necrosis factor alpha (TNF) (P 
itivity C-reactive protein (Hs-CRP) (P .002) in serum
1 year after hospital admission compared with surviving
ent in 259 patients with critical limb ischemia during
tality
up)
Amputation during
1 year (% subgroup)
Amputated-alive at
1 year (% amputees)
) 8 (17) 7 (88)
) 5 (24) 4 (80)
) 4 (12) 3 (75)
) 1 (3) 1 (100)
) 3 (6) 3 (100)
) 4 (36) 4 (100)
) 1 (17) 1 (100)
) 7 (13) 2 (29)
) 33 (13) 25 (76)kin-6
sens
rvivereatm
r mor
ubgro
1 (24
4 (18
7 (21
5 (15
0 (19
4 (36
2 (33
8 (34
1 (24disease.3 Surprisingly, in a small group of eight patients
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lesions,31 neither TNF- nor IL-6 differed from values in
healthy controls.
Because the relationships between inflammatory medi-
ators and mortality in our study persisted in the logistic
regression analysis and after exclusion of patients with
gangrene, these relationships may only partly be explained
by the fact that patients with inflammatory processes such
as gangrene of the extremities showed a high mortality.
Thus, our results indicate that the atherosclerotic process in
itself might explain part of the release of inflammatory
mediators.
Not surprisingly, age, leukocyte count, and serum cre-
atinine levels were also associated with 1-year mortality in
our patients. This has been reported previously23 for leu-
kocyte count and creatinine. Furthermore, neutrophil
count has previously been shown to be associated with a
need for amputation in critical limb ischemia.32 This out-
come was not separately assessed in our study, however.
Well-established conventional risk factors for atherosclero-
sis such as blood pressure, diabetes mellitus, and smoking
showed no relationships with mortality in this aged popu-
lation already showing widespread atherosclerotic disease.
Concerning lipids, only a low serum level of HDL
cholesterol was associated with the 1-year mortality, and
other investigators have presented evidence for a similar
relationship with lipoprotein (a)33 that was not assessed in
our study. In this context, however, it has to be remem-
bered that the serum lipid levels often are falsely low among
patients with critical limb ischemia,34 and our lipid results
must therefore be interpreted with some caution.
The outcome of critical limb ischemia has previously
been reported to be worse in diabetic patients than in
nondiabetic patients,35 but surprisingly, the presence of
diabetes mellitus did not affect the 1-year mortality in our
patients. The duration of diabetes mellitus was not assessed,
so we cannot exclude the possibility that this lack of rela-
Table III. Logistic regression analysis with all variables di
year
Significance (P)
Male sex .525
Age* .0005
Gangrene .059
Lipid lowering drugs .115
No active treatment .341
Leukocyte count* .006
Serum creatinine* .653
HDL* .614
HS-CRP* .174
IL-6* .496
TNF* .486
Neopterin* .272
OR, Odds ratio; CI, confidence interval; HDL, high-density lipoprotein;
necrosis factor.
*Continuous variables, odds ratio is shown for an increase of one unit.tionship was due to a short duration of diabetes mellitus.Neither did we see any relationships between homocys-
teine, p-8-epi-PGF2, factor V Leyden, cardiolipin anti-
bodies, and 1-year mortality in our patients with critical
limb ischemia. In contrast to newly presented data36 con-
cerning the importance of the CD40 ligand in acute coro-
nary heart disease, we did not find any difference concern-
ing this variable between the survivors and the nonsurvivors
1 year after admission. In this context it must be remem-
bered that we, unlike Aggarwal et al,36 did not measure
CD40 ligand in coronary artery blood, and that this marker
might have different relevance in coronary and peripheral
atherosclerosis.
Apart from their well-documented effects upon the
mortality among patients with vascular disease, including
peripheral artery disease,37 statins favorably influence the
leg function38 and are associated with graft patency and
limb salvage after infrainguinal bypass surgery10 among
patients with peripheral arterial disease. It is therefore in-
teresting to note that statin use was more common in
survivors. This can hardly be interpreted as a causal relation,
however, because this was not a randomized study, and
statin treatment might have been prescribed mainly to
younger patients considered to have a better prognosis.
These results must therefore be evaluated with great cau-
tion.
It is also important to emphasize that we only corre-
lated laboratory variables recorded at admission to hospital
to 1-year mortality in this study. Possible effects on mortal-
ity because of medications added later, amputations, or
later surgical or endovascular interventions cannot be eval-
uated from this study but might be elucidated by further
follow-up. The mortality among amputees was surprisingly
low, however.
In conclusion, high plasma levels of the inflammatory
mediators TNF- and neopterin were associated with in-
creased 1-year mortality in subjects with critical limb isch-
emia. This effect was only partly caused by gangrene of the
g significantly between survivors and nonsurvivors after 1
OR
95% CI
Lower Upper
1.347 0.537 3.378
1.095 1.041 1.151
2.870 0.961 8.570
0.375 0.111 1.271
1.546 0.631 3.786
1.202 1.054 1.370
1.002 0.995 1.008
0.727 0.211 2.507
0.993 0.984 1.003
1.004 0.992 1.016
1.126 0.806 1.574
1.013 0.990 1.035
RP, high-sensitivity C-reactive protein; IL-6, interleukin-6; TNF, tumorfferin
HS-Caffected extremity.
JOURNAL OF VASCULAR SURGERY
July 200580 Barani et alWe thank Barbro Palmqvist and Pehr Ahlquist for their
skilful technical assistance.
REFERENCES
1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;
340:115-26.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis.
Circulation 2002;105:1135-43.
3. Silvestro A, Scopacasa F, Ruocco A, Oliva G, Sciano V, Zincarelli C, et
al. Inflammatory status and endothelial function in asymptomatic and
symptomatic peripheral arterial disease. Vasc Med 2003;8:225-32.
4. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion
molecule-1, soluble vascular adhesion molecule-1, and the develop-
ment of symptomatic peripheral arterial disease in men. Circulation
2002;106:820-5.
5. McDermott MM, Green D, Greenland P, Liu K, Criqui MH, Chan C,
et al. Relation of levels of hemostatic factors and inflammatory markers
to the ankle brachial index. Am J Cardiol 2003;92:194-9.
6. Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato AM,
Schiano V, et al. Endothelial dysfunction in peripheral arterial disease is
related to increase in plasma markers of inflammation and severity of
peripheral circulatory impairment but not to classic risk factors and
atherosclerotic burden. J Vasc Surg 2003;38:374-9.
7. Dormandy JA, Rutherford RB, TASC Working Group. TransAtlantic
Inter-Society Concensus (TASC). Management of peripheral arterial
disease (PAD). J Vasc Surg 2000;31:S170.
8. Bismuth J, Klitfod L, Sillesen H. The lack of cardiovascular risk factor
management in patients with critical limb ischaemia. Eur J Vasc Endo-
vasc Surg 2001;21:143-6.
9. Mukherjee D, Lingham P, Chetcuti S, Grossman PM, Moscucci M,
Luciano AE, et al. Missed opportunities to treat atherosclerosis in
patients undergoing peripheral vascular interventions. Insights from the
University of Michigan peripheral vascular disease quality improvement
initiative (PVD-QI2). Circulation 2002;106:1909-12.
10. Henke PM, Blackburn S, ProctorMC, Stevens J, Mukherjee D, Rajago-
palin S, et al. Patients undergoing infrainguinal bypass to treat athero-
sclerotic vascular disease are underprescribed cardioprotective medica-
tions: Effects on graft patency, limb salvage, and mortality. J Vasc Surg
2004;39:357-65.
11. Young JL, Libby P, Schönbeck U. Cytokines in the pathogenesis of
atherosclerosis. Thromb Haemost 2002;88:554-67.
12. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G, et al.
Elevated serum neopterin levels in atherosclerosis. Atherosclerosis
1991;89:203-8.
13. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
14. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res
2001;89:1092-103.
15. Schönbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek
U, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-
methylglutaryl coenzyme A reductase inhibitors limit CD40 and
CD40L expression in human vascular cells. Circulation 2002;106:
2888-93.
16. Newby DE, Webb DJ. The endothelin system in cardiovascular disease.
Br Med J 1997;314:531-2.
17. Ikeda U, Yamamoto K, Maeda Y, Shimpo M, Kanbe T, Shimada K.
Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle
cells. Hypertension 1997;29:65-9.
18. Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, et
al. In vivo formation of 8-iso-prostaglandin F and platelet activation in
diabetes mellitus; Effects of improved metabolic control and vitamin E
supplementation. Circulation 1999;99:224-9.
19. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ
2nd. A series of prostaglandin F2-like compounds are produced in vivo
in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.
Proc Natl Acad Sci USA 1990;87:9383-7.20. Patrono C, Fitzgerald GA. Isoprostanes: Potential Markers of Oxidant
Stress in Atherothrombotic Disease. Arterioscler Thromb Vasc Biol
1997;17:2309-15.
21. Wolfe JN. Defining the outcome of critical ischaemia: a one year
prospective study. Br J Surg 1986;73:321.
22. The I.C.A.I. Group. Long term mortality and its predictors in patients
with critical leg ischaemia. Eur J Vasc Endovasc Surg 1997;14:91-5.
23. Pedrinelli R, Dell=OmoG, Barchielli A, Berchiolli R, Melillo E, Mariani
M, et al. Fibrinogen and mortality in chronic critical limb ischaemia.
J Intern Med 1999;245:75-81.
24. Burstein M, Scholnik HR, Morfin R. Rapid method for the isolation of
proteins from human serum by precipitation with polyanions. J Lipid
Res 1970;11:583-95.
25. Ubbink J, Vermaak W, Bissbort S. Rapid high-performance liquid
chromatographic assay for total homocystein levels in human serum.
J Chromatogr 1991;565:441-6.
26. Fiskerstrand T, Refsum H, Kvalheim G, Ueland P. Homocysteine and
other thiols in plasma and urine: Automated determination and sample
stability. Clin Chem 1993;39:263-71.
27. Norlund L, Grubb A, Fex G, Leksell H, Nilsson J, Schenk H, et al. The
increase of plasma homocysteine concentrations with age is partly due
to the deterioration of renal function as determined by plasma cystatin
C. Clin Chem Lab Med 1998;36:175-8.
28. Hillarp A, Zöller B, Dahlbäck B. Activated protein C resistance as a basis
for venous thrombosis. Am J Med 1996;101:534-40.
29. Brostoff J, Scadding GK, Male D, Roitt IM. In: Clinical Immunology.
Philadelphia: JB Lippincott Company, Gower Medical Publishing;
1991:6.6-6.7.
30. Testa M, DeRuvo E, Russo A, Citterio F, Serino F, Mangoni A, et al.
Induction of interleukin-1beta and interleukin-6 gene expression in
hypoperfused skeletal muscle of patients with peripheral arterial disease.
Ital Heart J 2000;1:64-7.
31. Fiotti N, Giansante C, Ponte E, Delbello C, Calabrese S, Zacchi T, et al.
Atherosclerosis and inflammation. Patterns of cytokine regulation in
patients with peripheral arterial disease. Atherosclerosis 1999;145:51-
60.
32. Belch JJ, Songhen M, Robb R, Voleske P, Sohngen W. Neutrophil
count and amputation in critical limb ischaemia. Int Angiol 1999;18:
140-4.
33. Cheng SWK, Ting ACW. Lipoprotein (a) level and mortality in patients
with critical lower limb ischaemia. Eur J Vasc Endovasc Surg 2001;22:
124-9.
34. Bismuth J, Kofoed SC, Jensen AS, Sethi A, Sillesen H. Serum lipids act
as inverse acute phase reactants and are falsely low in patients with
critical limb ischemia. J Vasc Surg 2002;36:1005-10.
35. Da Silva AF, Desgranges P, Holdsworth J, Harris PL, McCollum P,
Jones SM, et al. The management and outcome of critical limb isch-
aemia in diabetic patients: results of a national survey. Audit committee
of the Vascular Surgical Society of Great Britain and Ireland. Diabet
Med 1996;13:726-8.
36. Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL.
Increased coronary arterial release of interleukin-1 receptor antagonist
and soluble CD40 ligand indicative of inflammation associated with
culprit coronary plaques. Am J Cardiol 2004;93:6-9.
37. Heart Protection Study Collaborative Group. MRC/BHF Heart Pro-
tection Study of cholesterol lowering with simvastatin in 20536 high-
risk individuals: a randomised placebo-controlled trial. Lancet 2002;
360:7-22.
38. McGraeMcDermottM, Guralnik JM, Greenland P, PearceWH, Criqui
MH, Liu K, et al. Statin use and leg functioning in patients with and
without lower-extremity peripheral arterial disease. Circulation 2003;
107:757-61.Submitted Jan 27, 2005; accepted Mar 9, 2005.
